REVIEW PAPER
IgA vasculitis, formerly known as Henoch-Schönlein purpura
– the most common vasculitis in children
Submission date: 2018-05-30
Final revision date: 2018-06-24
Acceptance date: 2018-06-29
Publication date: 2018-08-30
Pediatr Pol 2018;93(4):336-342
KEYWORDS
TOPICS
ABSTRACT
Henoch-Schonlein purpura (HSP) is the most common systemic vasculitis in children. It belongs to the group of small-vessel vasculitis associated with immune complexes, and the proper term is IgA vasculitis (IgAV). In HSP in the wall of small vessels, deposits of immune complexes composed of IgA1 and C3 complement component are found. The incidence of HSP is estimated at 3–26.7/100,000 children per year. The changes most often affect the skin, lower limbs, digestive tract, and kidneys and are accompanied by arthralgia and arthritis. In this review article we pay attention to the pathogenesis, possible clinical manifestations, irregularities in laboratory tests, and proper management of patients with HSP. The treatment should depend on the clinical condition of the patient and is primarily symptomatic. Good knowledge of the differentiation of clinical symptoms allows for quick diagnosis and the qualification of patients for appropriate supervision.
REFERENCES (60)
1.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
2.
Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein): current state of knowledge. Curr Opin Rheumatol 2013; 25: 171-178.
3.
Aalberse J, Dolman K, Ramnath G, et al. Henoch Schonlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. Ann Rheum Dis 2007; 66: 1648-1650.
4.
Peru H, Soylemezoglu O, Bakkaloglu SA, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008; 27: 1087-1092.
5.
Ghrahani R, Ledika MA, Sapartini G, et al. Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura. Asia Pac Allergy 2014; 4: 42-47.
6.
González LM, Janniger CK, Schwartz RA. Pediatric Henoch-Schönlein purpura. Int J Dermatol 2009; 48: 1157-1165.
7.
Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360: 1197-1202.
8.
Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35: 143-153.
9.
Atkinson SR, Barker DJ. Seasonal distribution of Henoch-Schönlein purpura. Br J Prev Soc Med 1976; 30: 22-25.
10.
Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69: 798-806.
11.
Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990; 33: 1114-1121.
12.
Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schönlein purpura: an updated review. Autoimmun Rev 2014; 13: 355-358.
13.
He X, Yu C, Zhao P, et al. The genetics of Henoch-Schönlein purpura: a systematic review and meta-analysis. Rheumatol Int 2013; 33: 1387-1395.
14.
López-Mejías R, Genre F, Pérez BS, et al. Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Res Ther 2015; 17: 102.
15.
Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev 2017; 16: 1246-1253.
16.
Aleyd E, Heineke MH, van Egmond M. The era of the immunoglobulin A Fc receptor FcalphaRI; its function and potential as target in disease. Immunol Rev 2015; 268: 123-138.
17.
Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes.J Biol Chem 2014; 289: 5330-5339.
18.
Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677.
19.
Novak J, Rizk D, Takahashi K, et al. New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis 2015; 1: 8-18.
20.
Yang YH, Wang SJ, Chuang YH, et al. The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-α treatment in children with Henoch-Schönlein purpura. Clin Exp Immunol 2002; 130: 352-357.
21.
Belizna C, Duijvestijn A, Hamidou M, et al. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis 2006; 65: 1545-1550.
22.
Ghersetich I, Buggiani G, Brazzini B, et al. Cutaneous small-vessel vasculitis. Gital Dermatol Venereol 2004; 139: 389-413.
23.
Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-2868.
24.
Kimura S, Takeuchi S, Soma Y. Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura. Clin Exp Dermatol 2013; 38: 730-736.
25.
Yang Z, Liang Y, Xi W, et al. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011; 11: 75-80.
26.
Chen T, Jia R, Guo Z, et al. Elevated serum interleukin-33 levels in patients with Henoch-Schönlein purpura. Arch Dermatol Res 2013; 305: 173-177.
27.
Wang YB, Shan NN, Chen O, et al. Imbalance of interleukin-18 and interleukin-18 binding protein in children with Henoch-Schönlein purpura. J Int Med Res 2011; 39: 2201-2208.
28.
Jen HY, Chuang YH, Lin SC, et al. Increased serum interleukin‐17 and peripheral Th17 cells in children with acute Henoch-Schönlein purpura. Pediatr Allergy Immunol 2011; 22: 862-868.
29.
Rigante D, Castellazzi L, Bosco A, et al. Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura? Autoimmun Rev 2013; 12: 1016-1021.
30.
Min Z, Garcia RR, Murillo M, et al. Vancomycin-associated Henoch-Schönlein purpura. J Infect Chemother 2017; 23: 180-184.
31.
Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36: 130-147.
32.
Watanabe T. Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1). Pediatr Nephrol 2011; 26: 795-798.
33.
Jariwala S, Vernon N, Shliozberg J. Henoch-Schönlein purpura after hepatitis A vaccination. Ann Allergy Asthma Immunol 2011; 107: 180-181.
34.
Mitsui H, Shibagaki N, Kawamura T, et al. A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol 2009; 23: 394-401.
35.
Blanco R, González-Gay MA, Ibánez D, et al. Henoch-Schönlein purpura as a clinical presentation of small cell lung cancer. Clin Exp Rheumatol 1997; 15: 545-547.
36.
Angelier AS, Petit L, Wynckel A, et al. Schoenlein-Henoch purpura as a presentation of squamous cell bronchial carcinoma. Rev Mal Respir 2011; 28: 372-376.
37.
Nozato K, Morishima Y, Furuta J, et al. A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib. Nihon Kokyuki Gakkai Zasshi 2010; 48: 529-534.
38.
Jamrozik A, Sybilski A, Pohorecka M, et al. Zespół Schönleina-Henocha – nowe wyzwania diagnostyczne w starej chorobie. Pediatr Med Rodz 2012; 8: 214-221.
39.
Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health 2013; 49: 995-1003.
40.
Bluman J, Goldman RD. Henoch-Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician 2014; 60: 1007-1010.
41.
Jauhola O, Ronkainen J, Koskimies O, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 2010; 95: 871-876.
42.
Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet 2007; 369: 976-978.
43.
Trapani S, Micheli A, Grisolia F, et al. Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35: 143-153.
44.
García-Porrúa C, Calvińo MC, Llorca J, et al. Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. Semin Arthritis Rheum 2002; 32: 149-156.
45.
Özkaya AK, Güler E, Çetinkaya A. Henoch-Schönlein purpura complicated by acalculous cholecystitis and intussusception, and following recurrence with appendicitis. Paediatr Int Child Health 2016; 36: 157-159.
46.
Huang DY, Li Q, Jiang KR, et al. Henoch-Schönlein Purpura: A Rare Cause of Recurrent Acute Pancreatitis. Chin Med J (Engl) 2016; 129: 2510-2511.
47.
Kumar L, Singh S, Goraya JS, et al. Henoch Schonlein purpura: The Chandigarh experience. Indian Pediatr 1998; 35: 19-25.
48.
Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 2002; 360: 666-670.
49.
Watson L, Richardson AR, Holt RC, et al. Henoch schonlein purpura – a 5-year review and proposed pathway. PLoS One 2012; 7: e29512.
50.
Zhao YL, Liu ZJ, Bai XM, et al. Obesity increases the risk of renal involvement in children with Henoch-Schönlein purpura. Eur J Pediatr 2015; 174: 1357-1363.
51.
Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90: 916-920.
52.
Modi S, Mohan M, Jennings A. Acute Scrotal Swelling in Henoch-Schonlein Purpura: Case Report and Review of the Literature. Urol Case Rep 2016; 6: 9-11.
53.
Dos Santos D, Langer FW, Dos Santos T, et al. Posterior reversible encephalopathy syndrome as a complication of Henoch-Schönlein purpura in a seven-year-old girl. Scott Med J 2017; 62: 34-37.
54.
Hwang JJ, Ahn J, Kim KP, et al. Henoch-Schönlein Purpura With Muscle Involvement, Presenting as Myositis. J Clin Rheumatol 2017; 23: 60-62.
55.
Michas G, Grigoriou K, Syrigos D, et al. A rare cause of myocarditis resulting in acute heart failure in the setting of Henoch-Schönlein purpura. Hellenic J Cardiol 2017; 58: 439-442.
56.
Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management, World J Pediatr 2015; 11: 29.
57.
Bluman J, Goldman RD. Henoch-Schönlein purpura in children- Limited benefit of corticosteroids. Can Fam Physician 2014; 60: 1007-1010.
58.
Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP). Cochrane Database Syst Rev 2009; 3: CD005128.
59.
Weiss PF, Klink AJ, Localio R, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics 2010; 126: 674-681.
60.
Saulsbury FT. Henoch-Schonlein Purpura in children: report of 100 patients and review of the literature. Medicine 1999; 78: 395-409.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
